Carolin M. Lieber

Developmental candidate GHP-88310/EIDD-3608 with high tolerability and oral efficacy in measles and respiratory paramyxovirus models

This paper develops a new antiviral compound, GHP-88310, showing high tolerability and oral efficacy against measles and respiratory paramyxoviruses in animal models.

Impact of Mutations Affecting 4'-Fluorouridine Susceptibility on Fitness and Treatment Outcomes for Venezuelan Equine Encephalitis Virus

This study identifies mutations in VEEV nsP4 that reduce susceptibility to 4-FlU, shows these mutations do not fully prevent 4-FlU's therapeutic effect in mice, and highlights its potential as an antiviral for alphavirus encephalitis.

SARS-CoV-2 causes chronic lung inflammation and impaired respiratory capacity in aged Roborovski dwarf hamsters

This study shows that aged Roborovski dwarf hamsters infected with SARS-CoV-2 develop severe lung inflammation, impaired respiratory function, and chronic pneumonia, which can be mitigated by antiviral treatment.

Reprogramming of alveolar macrophages by intestinal segmented filamentous bacteria protects mice from lethal bacterial pneumoniae following influenza infection

SFB colonization reprograms alveolar macrophages to resist depletion and enhance bacterial clearance post-influenza infection.

Efficacy of late-onset antiviral treatment in immune-compromised hosts with persistent SARS-CoV-2 infection

This study evaluates late-onset antiviral treatment in immunocompromised mice with persistent SARS-CoV-2 infection, finding that 4-FlU significantly reduces virus load, while paxlovid causes viral rebound.